89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
| ETNB Stock | USD 8.99 0.15 1.64% |
About 56% of 89bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 89bio Inc suggests that many traders are alarmed. The current market sentiment, together with 89bio's historical and current headlines, can help investors time the market. In addition, many technical investors use 89bio Inc stock news signals to limit their universe of possible portfolio assets.
89bio |
Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine presented the data in a late-breaker session at the EASL International Liver Congress Discussions with regulatory agencies regarding Phase 3 NASH program are planned for the second half of 2023 Initiated ENTRUST Phase 3 trial of pegozafermin in patients with severe hypertriglyceridemia Published positive results from Phase 2 ENTRIGUE trial of pegozafermin in SHTG in Nat
Read at finance.yahoo.com
 |
89bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 89bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
89bio Fundamental Analysis
We analyze 89bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 89bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 89bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
89bio is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
89bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 89bio stock to make a market-neutral strategy. Peer analysis of 89bio could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics with similar companies.
Peers
89bio Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| HEPA | Hepion Pharmaceuticals | 4.69 | ||||
| PLRX | Pliant Therapeutics | 2.00 | ||||
| STOK | Stoke Therapeutics | 1.68 | ||||
| HOOK | Hookipa Pharma | 1.61 | ||||
| DAWN | Day One | 1.53 | ||||
| MREO | Mereo BioPharma | 1.40 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| AKRO | Akero Therapeutics | 0.22 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| TGTX | TG Therapeutics | 0.57 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
| ACLX | Arcellx | 1.12 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| VKTX | Viking Therapeutics | 2.88 |
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |